{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:10:52Z","timestamp":1788999052972,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA021765"],"award-info":[{"award-number":["P30CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    MCL-1 (myeloid cell leukemia-1) promotes survival and confers therapeutic resistance in acute myeloid leukemia (AML), particularly in high-risk subtypes harboring\n                    <jats:italic>KMT2A<\/jats:italic>\n                    rearrangements (\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r). Clinical trials involving patients with hematological malignancies treated with MCL-1 inhibitor monotherapy have been hampered by dose-limiting toxicity and poor response rates. Therefore, we sought to identify combinatorial treatment approaches to enhance the efficacy of MCL-1 inhibitors with the goal of improving response rates and limiting toxicities. Here, we report the inhibition of electron transport chain (ETC) complex I (CI) function as a synthetic lethal partner for MCL-1 inhibition. Co-targeting CI and MCL-1 synergistically reduces the viability in AML cell lines and patient-derived xenograft (PDX) samples in vitro, while significantly prolonging survival in mice bearing PDX AML, indicating the preclinical potential for this combinatorial therapy. These findings provide a mechanistic rationale and preclinical evidence for dual inhibition of MCL-1 and CI as a therapeutic strategy, offering a potential path to overcome resistance to single-agent MCL-1 inhibitors and improve outcomes for patients with high-risk AML. Mechanistically, we reveal that CI inhibition induces the activation of the integrated stress response, resulting in ATF4 activation downstream of the eIF2\u03b1 kinase, HRI (Heme-regulated inhibitor). HRI activation via CI inhibition is dependent on the mitochondrial stress messenger, DELE1. Together, these results indicate that co-inhibition of MCL-1 and ETC CI function has the potential for improving responses in patients with\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r AML.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09037-w","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:06:42Z","timestamp":1782385602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemia"],"prefix":"10.1038","volume":"17","author":[{"given":"Lauren","family":"Brakefield-Laird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-8608","authenticated-orcid":false,"given":"Amit","family":"Budhraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie","family":"Brewington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2504-8657","authenticated-orcid":false,"given":"Josi","family":"Lott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Voronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grant-Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tresor O.","family":"Mukiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristen","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-9216","authenticated-orcid":false,"given":"Yong-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandi","family":"Radko-Juettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-585X","authenticated-orcid":false,"given":"Shondra M.","family":"Pruett-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Pounds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1147-5621","authenticated-orcid":false,"given":"Joseph T.","family":"Opferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"9037_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. \u2018Acute myeloid leukemia: a comprehensive review and 2016 update\u2019. Blood Cancer J. 2016;6:e441.","journal-title":"Blood Cancer J"},{"key":"9037_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11:162.","journal-title":"Blood Cancer J"},{"key":"9037_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","volume":"37","author":"JE Chipuk","year":"2010","unstructured":"Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37:299\u2013310.","journal-title":"Mol Cell"},{"key":"9037_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13046-021-02157-5","volume":"40","author":"PA Townsend","year":"2021","unstructured":"Townsend PA, Kozhevnikova MV, Cexus ONF, Zamyatnin AA Jr, Soond SM. BH3-mimetics: recent developments in cancer therapy. J Exp Clin Cancer Res. 2021;40:355.","journal-title":"J Exp Clin Cancer Res"},{"key":"9037_CR5","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"9037_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"9037_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.14251","volume":"179","author":"C Dousset","year":"2017","unstructured":"Dousset C, Maiga S, Gomez-Bougie P, Le Coq J, Touzeau C, Moreau P, et al. BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. Br J Haematol. 2017;179:684\u20138.","journal-title":"Br J Haematol"},{"key":"9037_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.","journal-title":"BMC Cancer"},{"key":"9037_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep27696","volume":"6","author":"KH Lin","year":"2016","unstructured":"Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, et al. Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci Rep. 2016;6:27696.","journal-title":"Sci Rep"},{"key":"9037_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7:51.","journal-title":"Signal Transduct Target Ther"},{"key":"9037_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"9037_CR12","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D\u2019Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1:1176\u201387.","journal-title":"Nat Cancer"},{"key":"9037_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.","journal-title":"Nat Commun"},{"key":"9037_CR14","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","volume":"63","author":"Z Szlavik","year":"2020","unstructured":"Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, et al. Discovery of S64315, a potent and selective Mcl-1 inhibitor. J Med Chem. 2020;63:13762\u201395.","journal-title":"J Med Chem"},{"key":"9037_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","volume":"3","author":"J Yuda","year":"2023","unstructured":"Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med. 2023;3:154.","journal-title":"Commun Med"},{"key":"9037_CR16","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","volume":"30","author":"P Desai","year":"2024","unstructured":"Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O\u2019Brien S, et al. A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed\/refractory hematologic malignancies. Clin Cancer Res. 2024;30:4844\u201355.","journal-title":"Clin Cancer Res"},{"key":"9037_CR17","doi-asserted-by":"publisher","first-page":"807266","DOI":"10.3389\/fonc.2022.807266","volume":"12","author":"Y Mesbahi","year":"2022","unstructured":"Mesbahi Y, Trahair TN, Lock RB, Connerty P. Exploring the metabolic landscape of AML: from haematopoietic stem cells to myeloblasts and leukaemic stem cells. Front Oncol. 2022;12:807266.","journal-title":"Front Oncol"},{"key":"9037_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55231-9","volume":"15","author":"D Forte","year":"2024","unstructured":"Forte D, Pellegrino RM, Falvo P, Garcia-Gonzalez P, Alabed HBR, Maltoni F, et al. Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia. Nat Commun. 2024;15:10878.","journal-title":"Nat Commun"},{"key":"9037_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341.","journal-title":"Cell Stem Cell"},{"key":"9037_CR20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","volume":"34","author":"CL Jones","year":"2018","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724\u201340.e4.","journal-title":"Cancer Cell"},{"key":"9037_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.tcb.2014.04.001","volume":"24","author":"L Kohli","year":"2014","unstructured":"Kohli L, Passegue E. Surviving change: the metabolic journey of hematopoietic stem cells. Trends Cell Biol. 2014;24:479\u201387.","journal-title":"Trends Cell Biol"},{"key":"9037_CR22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/nm.4399","volume":"23","author":"EM Kuntz","year":"2017","unstructured":"Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med. 2017;23:1234\u201340.","journal-title":"Nat Med"},{"key":"9037_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19:23\u201337.","journal-title":"Cell Stem Cell"},{"key":"9037_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2174\/092986709787846578","volume":"16","author":"LK Sharma","year":"2009","unstructured":"Sharma LK, Lu J, Bai Y. Mitochondrial respiratory complex I: structure, function and implication in human diseases. Curr Med Chem. 2009;16:1266\u201377.","journal-title":"Curr Med Chem"},{"key":"9037_CR25","doi-asserted-by":"crossref","unstructured":"Mick E, Titov DV, Skinner OS, Sharma R, Jourdain AA, Mootha VK. Distinct mitochondrial defects trigger the integrated stress response depending on the metabolic state of the cell. eLife. 2020;9:e49178.","DOI":"10.7554\/eLife.49178"},{"key":"9037_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326.","journal-title":"Nat Med"},{"key":"9037_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036\u201346.","journal-title":"Nat Med"},{"key":"9037_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/leu.2013.107","volume":"27","author":"S Scotland","year":"2013","unstructured":"Scotland S, Saland E, Skuli N, de Toni F, Boutzen H, Micklow E, et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia. 2013;27:2129\u201338.","journal-title":"Leukemia"},{"key":"9037_CR29","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10637-022-01277-9","volume":"40","author":"F Janku","year":"2022","unstructured":"Janku F, Beom SH, Moon YW, Kim TW, Shin YG, Yim DS, et al. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2022;40:1001\u201310.","journal-title":"Invest New Drugs"},{"key":"9037_CR30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2023020142","volume":"142","author":"Y Liu","year":"2023","unstructured":"Liu Y, Kimpara S, Hoang NM, Daenthanasanmak A, Li Y, Lu L, et al. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023;142:1879\u201394.","journal-title":"Blood"},{"key":"9037_CR31","doi-asserted-by":"publisher","first-page":"C684","DOI":"10.1152\/ajpcell.00114.2014","volume":"307","author":"S Marriott","year":"2014","unstructured":"Marriott S, Baskir RS, Gaskill C, Menon S, Carrier EJ, Williams J, et al. ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. Am J Physiol Cell Physiol. 2014;307:C684\u201398.","journal-title":"Am J Physiol Cell Physiol"},{"key":"9037_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41418-018-0118-3","volume":"26","author":"S Hubackova","year":"2019","unstructured":"Hubackova S, Davidova E, Rohlenova K, Stursa J, Werner L, Andera L, et al. Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death Differ. 2019;26:276\u201390.","journal-title":"Cell Death Differ"},{"key":"9037_CR33","doi-asserted-by":"publisher","first-page":"101645","DOI":"10.1016\/j.xcrm.2024.101645","volume":"5","author":"M Chen","year":"2024","unstructured":"Chen M, Shen C, Chen Y, Chen Z, Zhou K, Chen Y, et al. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. Cell Rep Med. 2024;5:101645.","journal-title":"Cell Rep Med"},{"key":"9037_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30396-3","volume":"13","author":"N Baran","year":"2022","unstructured":"Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, et al. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022;13:2801.","journal-title":"Nat Commun"},{"key":"9037_CR35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/bjh.18968","volume":"202","author":"L Hua","year":"2023","unstructured":"Hua L, Yang N, Li Y, Huang K, Jiang X, Liu F, et al. Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway. Br J Haematol. 2023;202:971\u201384.","journal-title":"Br J Haematol"},{"key":"9037_CR36","doi-asserted-by":"crossref","unstructured":"Liu F, Kalpage HA, Wang D, Edwards H, Huttemann M, Ma J, et al. Cotargeting of mitochondrial complex I and Bcl-2 shows antileukemic activity against acute myeloid leukemia cells reliant on oxidative phosphorylation. Cancers. 2020;12:2400.","DOI":"10.3390\/cancers12092400"},{"key":"9037_CR37","doi-asserted-by":"publisher","first-page":"100143","DOI":"10.1016\/j.xcrm.2020.100143","volume":"1","author":"R Masoud","year":"2020","unstructured":"Masoud R, Reyes-Castellanos G, Lac S, Garcia J, Dou S, Shintu L, et al. Targeting mitochondrial complex I overcomes chemoresistance in high OXPHOS pancreatic cancer. Cell Rep Med. 2020;1:100143.","journal-title":"Cell Rep Med"},{"key":"9037_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41586-020-2078-2","volume":"579","author":"X Guo","year":"2020","unstructured":"Guo X, Aviles G, Liu Y, Tian R, Unger BA, Lin YT, et al. Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway. Nature. 2020;579:427\u201332.","journal-title":"Nature"},{"key":"9037_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-020-2076-4","volume":"579","author":"E Fessler","year":"2020","unstructured":"Fessler E, Eckl EM, Schmitt S, Mancilla IA, Meyer-Bender MF, Hanf M, et al. A pathway coordinated by DELE1 relays mitochondrial stress to the cytosol. Nature. 2020;579:433\u20137.","journal-title":"Nature"},{"key":"9037_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1097-2765(03)00105-9","volume":"11","author":"HP Harding","year":"2003","unstructured":"Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11:619\u201333.","journal-title":"Mol Cell"},{"key":"9037_CR41","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1101\/gad.12.7.982","volume":"12","author":"H Zinszner","year":"1998","unstructured":"Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998;12:982\u201395.","journal-title":"Genes Dev"},{"key":"9037_CR42","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.cell.2007.04.027","volume":"129","author":"H Puthalakath","year":"2007","unstructured":"Puthalakath H, O\u2019Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129:1337\u201349.","journal-title":"Cell"},{"key":"9037_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13018-021-02257-0","volume":"16","author":"C Yang","year":"2021","unstructured":"Yang C, Zhuo W, Li Q, Huang C, Yan H, Jin D. Preliminary outcomes of allograft and hydroxyapatite as substitutes for autograft in anterior cervical discectomy and fusion with self-locking standalone cages. J Orthop Surg Res. 2021;16:123.","journal-title":"J Orthop Surg Res"},{"key":"9037_CR44","doi-asserted-by":"publisher","first-page":"eabj6877","DOI":"10.1126\/sciadv.abj6877","volume":"7","author":"Y Sun","year":"2021","unstructured":"Sun Y, Lin X, Liu B, Zhang Y, Li W, Zhang S, et al. Loss of ATF4 leads to functional aging-like attrition of adult hematopoietic stem cells. Sci Adv. 2021;7:eabj6877.","journal-title":"Sci Adv"},{"key":"9037_CR45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184\u201391.","journal-title":"Nat Biotechnol"},{"key":"9037_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson KR, Hanna RE, Hegde M, Donovan KF, Strand C, Sullender ME, et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun. 2018;9:5416.","journal-title":"Nat Commun"},{"key":"9037_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nbt.3235","volume":"33","author":"J Shi","year":"2015","unstructured":"Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33:661\u20137.","journal-title":"Nat Biotechnol"},{"key":"9037_CR48","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12:828\u201363.","journal-title":"Nat Protoc"},{"key":"9037_CR49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","volume":"162","author":"K Birsoy","year":"2015","unstructured":"Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162:540\u201351.","journal-title":"Cell"},{"key":"9037_CR50","doi-asserted-by":"publisher","first-page":"101270","DOI":"10.1016\/j.omtm.2024.101270","volume":"32","author":"M Bauler","year":"2024","unstructured":"Bauler M, Ferrara F, Lowe B, Beard JA, Wincek C, Wielgosz MM, et al. Genetic alteration of SJ293TS cells and modification of serum-free media enhances lentiviral vector production. Mol Ther Methods Clin Dev. 2024;32:101270.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"9037_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li W, Koster J, Xu H, Chen CH, Xiao T, Liu JS, et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 2015;16:281.","journal-title":"Genome Biol"},{"key":"9037_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013;14:128.","journal-title":"BMC Bioinform"},{"key":"9037_CR53","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"9037_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-0716-2990-1_6","volume":"2631","author":"S Narina","year":"2023","unstructured":"Narina S, Connelly JP, Pruett-Miller SM. High-throughput analysis of CRISPR-Cas9 editing outcomes in cell and animal models using CRIS.py. Methods Mol Biol. 2023;2631:155\u201382.","journal-title":"Methods Mol Biol"},{"key":"9037_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40896-w","volume":"9","author":"JP Connelly","year":"2019","unstructured":"Connelly JP, Pruett-Miller SM. CRIS.py: a versatile and high-throughput analysis program for CRISPR-based genome editing. Sci Rep. 2019;9:4194.","journal-title":"Sci Rep"},{"key":"9037_CR56","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1158\/1078-0432.CCR-17-1231","volume":"23","author":"A Budhraja","year":"2017","unstructured":"Budhraja A, Turnis ME, Churchman ML, Kothari A, Yang X, Xu H, et al. Modulation of navitoclax sensitivity by dihydroartemisinin-mediated MCL-1 repression in BCR-ABL(+) B-lineage acute lymphoblastic leukemia. Clin Cancer Res. 2017;23:7558\u201368.","journal-title":"Clin Cancer Res"},{"key":"9037_CR57","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genom Proteom Bioinf. 2022;20:587\u201396.","journal-title":"Genom Proteom Bioinf"},{"key":"9037_CR58","doi-asserted-by":"publisher","first-page":"e56380","DOI":"10.15252\/embr.202256380","volume":"24","author":"BR Desousa","year":"2023","unstructured":"Desousa BR, Kim KK, Jones AE, Ball AB, Hsieh WY, Swain P, et al. Calculation of ATP production rates using the Seahorse XF Analyzer. EMBO Rep. 2023;24:e56380.","journal-title":"EMBO Rep"},{"key":"9037_CR59","unstructured":"Romero NRG, Neilson A, Dranka BP. Quantifying cellular ATP production rate using agilent seahorse XF technology agilent technologies, Inc.; 2018 https:\/\/www.agilent.com\/cs\/library\/whitepaper\/public\/whitepaper-quantify-atp-production-rate-cell-analysis-5991-9303en-agilent.pdf?srsltid=AfmBOooWDptt-hatYX9Z4z4KQ6-e7C7lzN_1PLOO2vxv3RcSm-YcEe-g."},{"key":"9037_CR60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-4939-8861-7_4","volume":"1877","author":"C Fraser","year":"2019","unstructured":"Fraser C, Ryan J, Sarosiek K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. Methods Mol Biol. 2019;1877:61\u201376.","journal-title":"Methods Mol Biol"},{"key":"9037_CR61","doi-asserted-by":"publisher","first-page":"100461","DOI":"10.1016\/j.xpro.2021.100461","volume":"2","author":"EA Olesinski","year":"2021","unstructured":"Olesinski EA, Bhatt S. Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models. STAR Protoc. 2021;2:100461.","journal-title":"STAR Protoc"},{"key":"9037_CR62","doi-asserted-by":"crossref","unstructured":"Barajas JM, Phillips AH, Wang J, Thomas ME, Contreras L, Umeda M, et al. Tandem duplications in UBTF create XPO1-dependent nuclear export signals that reveal a leukemic therapeutic dependency. Blood Cancer Discov. 2026;7:51\u201367.","DOI":"10.1158\/2643-3230.BCD-25-0112"},{"key":"9037_CR63","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/biomet\/69.3.553","volume":"69","author":"DP Harrington","year":"1982","unstructured":"Harrington DP, Fleming TR. A class of rank test procedures for censored survival-data. Biometrika. 1982;69:553\u201366.","journal-title":"Biometrika"},{"key":"9037_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v081.i15","volume":"81","author":"R Oller","year":"2017","unstructured":"Oller R, Langohr K. FHtest: an R package for the comparison of survival curves with censored data. J Stat Softw. 2017;81:1\u201325.","journal-title":"J Stat Softw"},{"key":"9037_CR65","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451\u20138.","journal-title":"Br J Haematol"},{"key":"9037_CR66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","volume":"39","author":"SE Conneely","year":"2020","unstructured":"Conneely SE, Rau RE. The genomics of acute myeloid leukemia in children. Cancer Metastasis Rev. 2020;39:189\u2013209.","journal-title":"Cancer Metastasis Rev"},{"key":"9037_CR67","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","volume":"114","author":"BV Balgobind","year":"2009","unstructured":"Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489\u201396.","journal-title":"Blood"},{"key":"9037_CR68","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.20.03048","volume":"39","author":"JA Pollard","year":"2021","unstructured":"Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol. 2021;39:3149\u201360.","journal-title":"J Clin Oncol"},{"key":"9037_CR69","doi-asserted-by":"publisher","first-page":"e2115566119","DOI":"10.1073\/pnas.2115566119","volume":"119","author":"TD Jackson","year":"2022","unstructured":"Jackson TD, Crameri JJ, Muellner-Wong L, Frazier AE, Palmer CS, Formosa LE, et al. Sideroflexin 4 is a complex I assembly factor that interacts with the MCIA complex and is required for the assembly of the ND2 module. Proc Natl Acad Sci USA. 2022;119:e2115566119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9037_CR70","doi-asserted-by":"publisher","first-page":"111445","DOI":"10.1016\/j.celrep.2022.111445","volume":"41","author":"MS Prew","year":"2022","unstructured":"Prew MS, Adhikary U, Choi DW, Portero EP, Paulo JA, Gowda P, et al. MCL-1 is a master regulator of cancer dependency on fatty acid oxidation. Cell Rep. 2022;41:111445.","journal-title":"Cell Rep"},{"key":"9037_CR71","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.molcel.2024.02.035","volume":"84","author":"T Wright","year":"2024","unstructured":"Wright T, Turnis ME, Grace CR, Li X, Brakefield LA, Wang YD, et al. Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. Mol Cell. 2024;84:1338\u201353.e8.","journal-title":"Mol Cell"},{"key":"9037_CR72","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1126\/science.adw1836","volume":"389","author":"K Brinkmann","year":"2025","unstructured":"Brinkmann K, McArthur K, Malelang S, Gibson L, Tee A, Elahee Doomun SN, et al. Relative importance of the anti-apoptotic versus apoptosis-unrelated functions of MCL-1 in vivo. Science. 2025;389:1003\u201311.","journal-title":"Science"},{"key":"9037_CR73","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1074\/jbc.RA120.013366","volume":"295","author":"A Tsuji","year":"2020","unstructured":"Tsuji A, Akao T, Masuya T, Murai M. Miyoshi H. IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism. J Biol Chem. 2020;295:7481\u201391.","journal-title":"J Biol Chem"},{"key":"9037_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3324\/haematol.2020.260331","volume":"107","author":"BZ Carter","year":"2022","unstructured":"Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022;107:58\u201376.","journal-title":"Haematologica"},{"key":"9037_CR75","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.1059108","volume":"292","author":"MC Wei","year":"2001","unstructured":"Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727\u201330.","journal-title":"Science"},{"key":"9037_CR76","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u201365.","journal-title":"Cancer Cell"},{"key":"9037_CR77","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977\u201389.","journal-title":"Cell"},{"key":"9037_CR78","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1515\/hsz-2016-0107","volume":"397","author":"J Ryan","year":"2016","unstructured":"Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397:671\u20138.","journal-title":"Biol Chem"},{"key":"9037_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/srep05189","volume":"4","author":"AP Acharya","year":"2014","unstructured":"Acharya AP, Rafi M, Woods EC, Gardner AB, Murthy N. Metabolic engineering of lactate dehydrogenase rescues mice from acidosis. Sci Rep. 2014;4:5189.","journal-title":"Sci Rep"},{"key":"9037_CR80","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899\u2013905.","journal-title":"Nature"},{"key":"9037_CR81","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120\u20135.","journal-title":"Genes Dev"},{"key":"9037_CR82","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","volume":"10","author":"G Wei","year":"2006","unstructured":"Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10:331\u201342.","journal-title":"Cancer Cell"},{"key":"9037_CR83","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/mol.113.086140","volume":"84","author":"DL Hermanson","year":"2013","unstructured":"Hermanson DL, Das SG, Li Y, Xing C. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIbeta downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol Pharmacol. 2013;84:236\u201343.","journal-title":"Mol Pharmacol"},{"key":"9037_CR84","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","volume":"44","author":"AH Wei","year":"2020","unstructured":"Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 2020;44:100672.","journal-title":"Blood Rev"},{"key":"9037_CR85","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ncb2488","volume":"14","author":"RM Perciavalle","year":"2012","unstructured":"Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575\u201383.","journal-title":"Nat Cell Biol"},{"key":"9037_CR86","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/1541-7786.MCR-20-0586","volume":"19","author":"KH Smith","year":"2021","unstructured":"Smith KH, Budhraja A, Lynch J, Roberts K, Panetta JC, Connelly JP, et al. The heme-regulated inhibitor pathway modulates susceptibility of poor prognosis B-lineage acute leukemia to BH3-mimetics. Mol Cancer Res. 2021;19:636\u201350.","journal-title":"Mol Cancer Res"},{"key":"9037_CR87","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cmet.2021.02.001","volume":"33","author":"AS Krall","year":"2021","unstructured":"Krall AS, Mullen PJ, Surjono F, Momcilovic M, Schmid EW, Halbrook CJ, et al. Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth. Cell Metab. 2021;33:1013\u201326.e6.","journal-title":"Cell Metab"},{"key":"9037_CR88","doi-asserted-by":"publisher","first-page":"6998","DOI":"10.1158\/0008-5472.CAN-13-0940","volume":"73","author":"H Dai","year":"2013","unstructured":"Dai H, Ding H, Meng XW, Lee SH, Schneider PA, Kaufmann SH. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res. 2013;73:6998\u20137008.","journal-title":"Cancer Res"},{"key":"9037_CR89","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.molcel.2008.06.001","volume":"30","author":"Y Wei","year":"2008","unstructured":"Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008;30:678\u201388.","journal-title":"Mol Cell"},{"key":"9037_CR90","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1158\/0008-5472.CAN-18-0399","volume":"78","author":"J Tong","year":"2018","unstructured":"Tong J, Zheng X, Tan X, Fletcher R, Nikolovska-Coleska Z, Yu J, et al. Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-Only proteins. Cancer Res. 2018;78:4704\u201315.","journal-title":"Cancer Res"},{"key":"9037_CR91","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/febs.14505","volume":"285","author":"JE Conage-Pough","year":"2018","unstructured":"Conage-Pough JE, Boise LH. Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming. FEBS J. 2018;285:2626\u201340.","journal-title":"FEBS J"},{"key":"9037_CR92","doi-asserted-by":"publisher","first-page":"32340","DOI":"10.1074\/jbc.273.48.32340","volume":"273","author":"JJ Berlanga","year":"1998","unstructured":"Berlanga JJ, Herrero S, de Haro C. Characterization of the hemin-sensitive eukaryotic initiation factor 2alpha kinase from mouse nonerythroid cells. J Biol Chem. 1998;273:32340\u20136.","journal-title":"J Biol Chem"},{"key":"9037_CR93","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1073\/pnas.94.7.3279","volume":"94","author":"SD Der","year":"1997","unstructured":"Der SD, Yang YL, Weissmann C, Williams BR. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA. 1997;94:3279\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9037_CR94","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/16729","volume":"397","author":"HP Harding","year":"1999","unstructured":"Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature. 1999;397:271\u20134.","journal-title":"Nature"},{"key":"9037_CR95","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1097-2765(00)00028-9","volume":"6","author":"J Dong","year":"2000","unstructured":"Dong J, Qiu H, Garcia-Barrio M, Anderson J, Hinnebusch AG. Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell. 2000;6:269\u201379.","journal-title":"Mol Cell"},{"key":"9037_CR96","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0092-8674(77)90330-0","volume":"11","author":"PJ Farrell","year":"1977","unstructured":"Farrell PJ, Balkow K, Hunt T, Jackson RJ, Trachsel H. Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell. 1977;11:187\u2013200.","journal-title":"Cell"},{"key":"9037_CR97","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1091\/mbc.e05-03-0268","volume":"16","author":"RB Hamanaka","year":"2005","unstructured":"Hamanaka RB, Bennett BS, Cullinan SB, Diehl JA. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol Biol Cell. 2005;16:5493\u2013501.","journal-title":"Mol Biol Cell"},{"key":"9037_CR98","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1096\/fasebj.10.12.8903508","volume":"10","author":"C de Haro","year":"1996","unstructured":"de Haro C, Mendez R, Santoyo J. The eIF-2alpha kinases and the control of protein synthesis. FASEB J. 1996;10:1378\u201387.","journal-title":"FASEB J"},{"key":"9037_CR99","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10495-010-0519-3","volume":"15","author":"T Harada","year":"2010","unstructured":"Harada T, Iwai A, Miyazaki T. Identification of DELE, a novel DAP3-binding protein which is crucial for death receptor-mediated apoptosis induction. Apoptosis. 2010;15:1247\u201355.","journal-title":"Apoptosis"},{"key":"9037_CR100","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.yjmcc.2022.12.003","volume":"175","author":"H Huynh","year":"2023","unstructured":"Huynh H, Zhu S, Lee S, Bao Y, Pang J, Nguyen A, et al. DELE1 is protective for mitochondrial cardiomyopathy. J Mol Cell Cardiol. 2023;175:44\u20138.","journal-title":"J Mol Cell Cardiol"},{"key":"9037_CR101","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1038\/s44318-024-00242-x","volume":"43","author":"HP Lin","year":"2024","unstructured":"Lin HP, Petersen JD, Gilsrud AJ, Madruga A, D\u2019Silva TM, Huang X, et al. DELE1 maintains muscle proteostasis to promote growth and survival in mitochondrial myopathy. EMBO J. 2024;43:5548\u201385.","journal-title":"EMBO J"},{"key":"9037_CR102","doi-asserted-by":"crossref","unstructured":"Sui L, Zeng J, Zhao H, Ye L, Martin TA, Sanders AJ, et al. Death associated protein\u20113 (DAP3) and DAP3 binding cell death enhancer\u20111 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance. Int J Oncol. 2023;62:7.","DOI":"10.3892\/ijo.2022.5455"},{"key":"9037_CR103","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41375-023-02107-4","volume":"38","author":"JF Spinella","year":"2024","unstructured":"Spinella JF, Chagraoui J, Moison C, Lavallee VP, Boivin I, Gracias D, et al. DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5\/del(5q) AML. Leukemia. 2024;38:530\u20137.","journal-title":"Leukemia"},{"key":"9037_CR104","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbrc.2013.09.026","volume":"440","author":"KH Kim","year":"2013","unstructured":"Kim KH, Jeong YT, Kim SH, Jung HS, Park KS, Lee HY, et al. Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. Biochem Biophys Res Commun. 2013;440:76\u201381.","journal-title":"Biochem Biophys Res Commun"},{"key":"9037_CR105","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.nbd.2009.02.005","volume":"34","author":"JM Silva","year":"2009","unstructured":"Silva JM, Wong A, Carelli V, Cortopassi GA. Inhibition of mitochondrial function induces an integrated stress response in oligodendroglia. Neurobiol Dis. 2009;34:357\u201365.","journal-title":"Neurobiol Dis"},{"key":"9037_CR106","doi-asserted-by":"crossref","unstructured":"Ryan DG, Yang M, Prag HA, Blanco GR, Nikitopoulou E, Segarra-Mondejar M, et al. Disruption of the TCA cycle reveals an ATF4-dependent integration of redox and amino acid metabolism. eLife. 2021;10:e72593.","DOI":"10.7554\/eLife.72593"},{"key":"9037_CR107","doi-asserted-by":"publisher","first-page":"e1003866","DOI":"10.1371\/journal.pcbi.1003866","volume":"10","author":"MJ Prerau","year":"2014","unstructured":"Prerau MJ, Hartnack KE, Obregon-Henao G, Sampson A, Merlino M, Gannon K, et al. Tracking the sleep onset process: an empirical model of behavioral and physiological dynamics. PLoS Comput Biol. 2014;10:e1003866.","journal-title":"PLoS Comput Biol"},{"key":"9037_CR108","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","volume":"3","author":"A Slomp","year":"2019","unstructured":"Slomp A, Moesbergen LM, Gong JN, Cuenca M. von dem Borne PA, Sonneveld P, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3:4202\u201314.","journal-title":"Blood Adv"},{"key":"9037_CR109","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/bloodadvances.2019000499","volume":"3","author":"AM Stevens","year":"2019","unstructured":"Stevens AM, Xiang M, Heppler LN, Tosic I, Jiang K, Munoz JO, et al. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019;3:4215\u201327.","journal-title":"Blood Adv"},{"key":"9037_CR110","doi-asserted-by":"crossref","unstructured":"Stevens AM, Schafer ES, Li M, Terrell M, Rashid R, Paek H, et al. Repurposing atovaquone as a therapeutic against acute myeloid leukemia (AML): combination with conventional chemotherapy is feasible and well tolerated. Cancers. 2023;15:1344.","DOI":"10.3390\/cancers15041344"},{"key":"9037_CR111","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1152\/japplphysiol.01189.2009","volume":"108","author":"DJ Marcinek","year":"2010","unstructured":"Marcinek DJ, Kushmerick MJ, Conley KE. Lactic acidosis in vivo: testing the link between lactate generation and H+ accumulation in ischemic mouse muscle. J Appl Physiol. 2010;108:1479\u201386. 1985.","journal-title":"J Appl Physiol"},{"key":"9037_CR112","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3109\/02699052.2014.916821","volume":"28","author":"B Du","year":"2014","unstructured":"Du B, Wang J, Zhong XL, Liang J, Xiang W, Chen D, et al. Single versus bilateral external ventricular drainage for intraventricular fibrinolysis using urokinase in severe ventricular haemorrhage. Brain Inj. 2014;28:1413\u20136.","journal-title":"Brain Inj"},{"key":"9037_CR113","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1021\/acs.biochem.8b00626","volume":"57","author":"B Zhao","year":"2018","unstructured":"Zhao B, Arnold AL, Coronel MA, Lee JH, Lee T, Olejniczak ET, et al. Understanding the species selectivity of myeloid cell leukemia-1 (Mcl-1) inhibitors. Biochemistry. 2018;57:4952\u20138.","journal-title":"Biochemistry"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09037-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09037-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09037-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:02:47Z","timestamp":1788998567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09037-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9037"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09037-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Mice used in this study were bred and utilized in compliance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of SJCRH.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"785"}}